MK-1084
- Generic Name
- MK-1084
A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT06814119
- Locations
- 🇺🇸
Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
A Study of the Effect of Itraconazole and Phenytoin on MK-1084 in Healthy Adults (MK-1084-008)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06719557
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06687759
- Locations
- 🇺🇸
Fortea CRU Madison (Site 0001), Madison, Wisconsin, United States
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT06619314
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06575933
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06345729
- Locations
- 🇺🇸
CBCC Global Research, Inc. ( Site 0123), Bakersfield, California, United States
🇺🇸Beverly Hills Cancer Center ( Site 0116), Beverly Hills, California, United States
🇺🇸Mount Sinai Cancer Center ( Site 0137), Miami Beach, Florida, United States
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
- Conditions
- Metastatic Solid TumorsAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT05853367
- Locations
- 🇨🇱
Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703), Santiago, Region M. De Santiago, Chile
🇵🇱Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401), Warszawa, Mazowieckie, Poland
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 830
- Registration Number
- NCT05067283
- Locations
- 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.